AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOSCIENCE, INC. (also referred to as AYTU BIOPHARMA, INC.) on September 2, 2015, reporting events occurring on August 31, 2015. The company is a biopharmaceutical entity based in Englewood, Colorado, focused on clinical studies for Zertane and RedoxSYS, and the commercialization of ProstaScint.
Key Financial Metrics and Capital Structure
- Capital Raised: The company completed the third and final closing of a private placement, selling convertible promissory notes with an aggregate principal amount of $2,000,000. The total aggregate raised in the offering was $5,175,000.
- Debt Instrument: The notes are unsecured obligations maturing 18 months from issuance (January 22, February 11, and February 28, 2017), with an optional six-month extension.
- Interest Rates: Interest accrues at 8% simple interest per annum for the first six months, increasing to 12% thereafter. If a registration statement is not filed within six months, the rate increases to 14%.
- Conversion Terms: Notes are convertible at the holder's discretion into common stock at a price of $4.63 per share, with a 120% principal and accrued interest conversion factor. Mandatory conversion occurs upon a "Qualified Financing" (minimum $5,000,000 gross proceeds).
- Placement Agent Fees: Newbridge Securities Corporation received 8% of gross proceeds from the institutional portion plus a warrant for 8% of those proceeds.
Material Changes and Use of Proceeds
The primary material change is the completion of the $5.175 million debt financing. The company intends to use net proceeds for:
- Conducting clinical studies for Zertane and RedoxSYS.
- Working capital to begin commercializing FDA-approved ProstaScint.
- General corporate purposes.
Outlook, Risks, and Contingencies
- Registration Obligation: The company agreed to file a Form S-1 registration statement within five months of closing (by February 2016) and use best efforts to have it declared effective within 12 months of the initial closing (by July 2016).
- Liquidity Event Terms: In the event of a sale of the company, noteholders may elect to receive principal plus accrued interest plus a 25% premium on the original principal, or the consideration on an as-converted basis.
- Default Risks: Notes are subject to acceleration upon customary events of default. Failure to file the required registration statement triggers higher interest rates and subordination of notes held by officers and directors.
Investor Verification Checklist
- Verify the filing status and effectiveness date of the Form S-1 registration statement required by the note terms.
- Confirm the specific allocation of the $5,175,000 raised between institutional investors (via placement agent) and individual investors.
- Monitor the company's cash burn rate relative to the stated use of proceeds for clinical trials and commercialization.
- Review the terms of the placement agent warrant to assess potential future dilution.
- Check for any subsequent equity financings that may trigger mandatory conversion of the notes.